Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Cheng, AL; Qin, SK; Ikeda, M; Galle, PR; Ducreux, M; Kim, TY; Lim, HY; Kudo, M; Breder, V; Merle, P; Kaseb, AO; Li, DN; Verret, W; Ma, N; Nicholas, A; Wang, YF; Li, LD; Zhu, AX; Finn, RS

Cheng, AL (通讯作者)，Natl Taiwan Univ Hosp, 7 Chung Shan South Rd, Taipei 10002, Taiwan.;Cheng, AL (通讯作者)，Natl Taiwan Univ, Canc Ctr, 7 Chung Shan South Rd, Taipei 10002, Taiwan.;Finn, RS (通讯作者)，UCLA, Geffen Sch Med, Jonsson Comprehens Canc Ctr, 200 Med Plaza Driveway, Los Angeles, CA 90095 USA.

JOURNAL OF HEPATOLOGY, 2022; 76 (4): 862

Abstract

Background & Aims: IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索